Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004068 | 0.84 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2HTTCYP3A4CYP2D6 | |
| SCHEMBL7000340 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1SMN1; SMN2HTTCYP3A4 | |
| SCHEMBL7079144 | 0.83 | SMN1; SMN2 (0.45) | ALDH1A1MAPK1SMN1; SMN2DDR1HTT | |
| SCHEMBL7006943 | 0.81 | PDE5A (0.50) | ALDH1A1SMN1; SMN2YTHDC1TDP1HTT | |
| SCHEMBL7077422 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7001724 | 0.80 | TP53 (0.56) | ALDH1A1MAPK1SMN1; SMN2HTTTSHR | |
| SCHEMBL7077435 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MAPK1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL7003827 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2POLBLMNAKDM4E | |
| SCHEMBL7002718 | 0.80 | TRPA1 (0.48) | ALDH1A1SMN1; SMN2MKNK1MKNK2DDR1 | |
| SCHEMBL7006249 | 0.80 | ALDH1A1 (0.54) | ALDH1A1MAPK1SMN1; SMN2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | ELBION AG (DE) | 2003-10-02 | — | — | US | claimed |
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | ELBION AG (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1311510-A1 | 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002018387-A1 | 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ELBION AG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | DDO, GRIN3A, GRIK4 | ALDH1A1 568/4885MAPK1 3675/4885SMN1; SMN2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.